• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evogene Schedules Third Quarter 2024 Financial Results Release

    11/7/24 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email

    Zoom conference call scheduled for November 21, 2024, 9:00 AM ET

    REHOVOT, Israel, Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024.

    Evogene_Logo

    Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

    To join the conference, please register in advance:

    https://us06web.zoom.us/webinar/register/WN_pG-Wc0JeQIifu1dmSUYOng

    The entire conference will be available online on the company's website a few days after.

    About Evogene:

    Evogene Ltd. (NASDAQ:EVGN, TASE: EVGN)) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

    Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

    Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

    1. Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
    2. Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
    3. AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
    4. Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.

    For more information, please visit: www.evogene.com.

    Logo -  https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

    Contact

    [email protected]

    Tel: +972-8-9311901

    Cision View original content:https://www.prnewswire.com/news-releases/evogene-schedules-third-quarter-2024-financial-results-release-302298582.html

    SOURCE Evogene

    Get the next $EVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    SEC Filings

    View All

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    12/30/25 7:00:06 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    11/20/25 7:00:22 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form EFFECT filed by Evogene Ltd

    EFFECT - Evogene Ltd. (0001574565) (Filer)

    11/20/25 12:15:15 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

    Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform. This partnership aims to acceler

    1/7/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports Third Quarter 2025 Financial Results

    Conference call and webcast: today, November 20, 2025, 9:00 AM ET Financial Highlights: During the first nine months ending September 30, 2025, Evogene advanced its strategic transition toward establishing itself as a leader in computational chemistry, with a focus on the generative design of small molecules for the pharmaceutical and agricultural industries. As part of this new strategy, the company executed an organizational realignment and cost-reduction plan, most of which was completed by the end of the second quarter. The impact of these measures is reflected in the third-quarter results, with total operating expenses, net, of approximately $2.9 million compared to approximately $6.6 m

    11/20/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

    A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a range of diseases

    8/12/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

    Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

    3/6/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Schedules Third Quarter 2025 Financial Results Release

    Zoom conference call scheduled for November 20, 2025, 9:00 AM ET REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conf

    11/6/25 9:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports Second Quarter 2025 Financial Results

    Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

    8/19/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Second Quarter 2025 Financial Results Release

    Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

    7/29/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials